Nishikori Momoko

Affiliation and department：

Research field (1)： Hematology and oncology

Research theme for competitive and other funds (7)：

2021 - 2024 新規エピゲノム修飾薬のB細胞リンパ腫に対する奏効予測モデルの確立とその治療応用
2018 - 2021 Clarifying the significance of Notch signal activation in B-cell lymphomas
2015 - 2018 Clarifying the pathogenesis of ABC-DLBCL in a mouse model
2012 - 2015 Analysis of clonal hierarchy and microenvironment of the tumor developed in the mouse mantle cell lymphoma model
2008 - 2009 In vivo characterization of B cells with lymphoma-specific translocat in mice and their potential roles in lymphoma development.

Show all

Papers (100)：

Koji Kato, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Yoshinobu Maeda, Kenichi Yoshimura, Ukihide Tateishi, Toshihiro Miyamoto, Yasufumi Matsuda, Jun Ishikawa, et al. End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial. International journal of hematology. 2024. 119. 6. 677-685
Naokazu Nakamura, Tomoyasu Jo, Yasuyuki Arai, Toshio Kitawaki, Momoko Nishikori, Chisaki Mizumoto, Junya Kanda, Kouhei Yamashita, Miki Nagao, Akifumi Takaori-Kondo. Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy. Clinical and Experimental Medicine. 2024. 24. 1
Naokazu Nakamura, Tomoyasu Jo, Yasuyuki Arai, Toshio Kitawaki, Momoko Nishikori, Chisaki Mizumoto, Junya Kanda, Kouhei Yamashita, Miki Nagao, Akifumi Takaori-Kondo. Clinical impact of CRS on prolonged hematotoxicity after CAR-T cell therapy: KyoTox a-score, a novel prediction model. Transplantation and cellular therapy. 2024
Tomoyasu Jo, Yasuyuki Arai, Toshio Kitawaki, Naokazu Nakamura, Momoko Nishikori, Chisaki Mizumoto, Junya Kanda, Kouhei Yamashita, Miki Nagao, Akifumi Takaori-Kondo. KyoTox-e score; prediction of post-CAR-T prolonged thrombocytopenia using peripheral blood data before apheresis. Bone Marrow Transplantation. 2023
Koji Izutsu, Takahiro Kumode, Junichiro Yuda, Hirokazu Nagai, Yuko Mishima, Youko Suehiro, Kazuhito Yamamoto, Tomoaki Fujisaki, Kenji Ishitsuka, Kenichi Ishizawa, et al. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma. Cancer science. 2023. 114. 12. 4643-4653

ｍore...

MISC (90)：

菱澤方勝, 植田知代子, 岸本渉, 島津弥生, 濱田常義, 中村直和, 鈴木光太郎, 島津裕, 錦織桃子, 高折晃史, et al. CAR-T細胞療法後の再発に臍帯血移植で寛解が維持されたびまん性大細胞型B細胞リンパ腫の一例. 日本輸血細胞治療学会誌. 2024. 70. 1
田嶋哲也, 田嶋哲也, 秦浩一郎, 秦浩一郎, 日下部治郎, 日下部治郎, 宮内英孝, 宮内英孝, 万木紀美子, 菱田理恵, et al. 血液型不適合/既存ドナー特異的抗体陽性肝移植における抗体関連拒絶反応の発症危険因子は何か?. 日本移植学会総会プログラム抄録集. 2021. 57th (Web)
田嶋哲也, 秦浩一郎, 羽賀博典, 錦織桃子, 日下部治郎, 宮内英孝, 岡本竜弥, 小川絵里, 園田真理, 岡島英明, et al. 肝移植後リンパ増殖性疾患(PTLD)の頻度,治療とその予後~当院1,954例の後方視的解析から~. 日本外科学会定期学術集会(Web). 2021. 121st
牧野恭秀, 荒川芳輝, 丹治正大, 峰晴陽平, 錦織桃子, 高折晃史, 宇藤恵, 溝脇尚志, 宮本享. The current situation and problem of treatment for primary central nervous system lymphoma in elders. 日本脳腫瘍学会プログラム・抄録集. 2020. 38th
田嶋哲也, 秦浩一郎, 日下部治郎, 宮内英孝, 穴澤貴之, 錦織桃子, 海道利実, 羽賀博典, 高折晃史, 上本伸二. 血液型不適合肝臓移植の現状と課題 Rituximabによる術前減感作療法時代の血液型不適合成人生体肝移植の治療成績抗体関連拒絶反応発症の危険因子は何か?. 移植. 2019. 54. 総会臨時. 186-186

ｍore...

Lectures and oral presentations (48)：

濾胞性リンパ腫の病態と治療
(第127回日本血液学会東北地方会 2019)
Recent advances in the treatment of Hodgkin lymphoma.
(2018)
悪性リンパ腫の治療の新たな方向性
(第109回近畿血液学地方会 2018)
悪性リンパ腫の発症機序を考える
(日本血液学会学術集会 2016)
B細胞リンパ腫
(第8回研修医のための血液学セミナーランチョンセミナー 2016)

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page